The FLUNIVAC was funded by the European Commission under the FP7 program. The goal of FLUNIVAC was to develop a universal influenza vaccine that protects against multiple influenza virus strains. Artemis One Health was involved in the evaluation of induction of broad protective immune responses of vaccine candidates, using appropriate animal models. Several assays were developed to study immunogenicity and the longevity of the induced immunity. Assays such as hemagglunitation inhibition, antibody-dependent cell cytotoxicity, different ELISA, neutralization test were developed and used in this project.